KalVista Pharmaceuticals Ownership | Who Owns KalVista Pharmaceuticals?
KalVista Pharmaceuticals Ownership Summary
KalVista Pharmaceuticals is owned by 113.34% institutional investors, 1.31% insiders. Vr adviser is the largest institutional shareholder, holding 12.58% of KALV shares. American Funds SMALLCAP World A is the top mutual fund, with 6.36% of its assets in KalVista Pharmaceuticals shares.
KALV Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | KalVista Pharmaceuticals | 113.34% | 1.31% | -14.65% |
| Sector | Healthcare Stocks | 42.54% | 10.83% | 46.63% |
| Industry | Biotech Stocks | 45.22% | 10.75% | 44.04% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vr adviser | 6.73M | 12.58% | $81.96M |
| Tang capital management | 5.04M | 9.42% | $61.41M |
| Frazier life sciences management | 5.04M | 9.42% | $61.39M |
| Suvretta capital management | 4.77M | 8.91% | $58.08M |
| Blackrock | 2.95M | 6.76% | $34.69M |
| Capital world investors | 3.18M | 5.94% | $38.70M |
| Blackrock funding, inc. /de | 3.13M | 5.84% | $38.08M |
| Vanguard group | 2.50M | 4.68% | $30.46M |
| Tudor investment corp et al | 2.00M | 3.74% | $2.18M |
| Boxer capital | 1.59M | 3.65% | $18.73M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Allostery investments lp | 40.00K | 5.76% | $452.20K |
| Vr adviser | 6.73M | 4.61% | $81.96M |
| Tang capital management | 5.04M | 2.36% | $61.41M |
| Octagon capital advisors lp | 1.27M | 2.35% | $15.51M |
| Silverarc capital management | 1.36M | 2.24% | $16.61M |
| Parkman healthcare partners | 1.74M | 2.20% | $21.13M |
| Sio capital management | 683.82K | 2.11% | $8.33M |
| Frazier life sciences management | 5.04M | 1.84% | $61.39M |
| Suvretta capital management | 4.77M | 1.49% | $58.08M |
| Dafna capital management | 422.73K | 1.27% | $5.15M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Tudor investment corp et al | 2.00M | 0.00% | 2.00M |
| Goldman sachs group | 1.80M | 0.00% | 1.67M |
| Parkman healthcare partners | 1.74M | 2.20% | 1.06M |
| Freestone grove partners lp | 704.45K | 0.06% | 704.45K |
| Sio capital management | 683.82K | 2.11% | 683.82K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Vestal point capital, lp | 750.00K | 0.41% | -3.92M |
| Tcg crossover management | - | - | -1.16M |
| Ameriprise financial | 35.45K | 0.00% | -909.68K |
| Bioimpact capital | - | - | -896.91K |
| Driehaus capital management | - | - | -535.72K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Tudor investment corp et al | 2.00M | 0.00% | 2.00M | $2.18M |
| Freestone grove partners lp | 704.45K | 0.06% | 704.45K | $8.58M |
| Sio capital management | 683.82K | 2.11% | 683.82K | $8.33M |
| Kynam capital management, lp | 606.17K | 0.55% | 606.17K | $7.38M |
| Summittx capital | 143.56K | 0.07% | 143.56K | $1.75M |
Sold Out
| Holder | Change |
|---|---|
| National bank of canada /fi/ | -1.00 |
| Fortitude family office | -3.00 |
| Ifp advisors | -4.00 |
| Nelson, van denburg & campbell wealth management group | -5.00 |
| Creekmur asset management | -23.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | 148 | 1.37% | 60,631,934 | 11.36% | 113 | 0.94% | 75 | -7.41% | 39 | 11.43% |
| Jun 30, 2025 | 145 | 5.07% | 54,415,240 | -0.92% | 109 | 1.01% | 80 | 12.68% | 35 | -7.89% |
| Mar 31, 2025 | 138 | 5.34% | 54,920,723 | -0.49% | 104 | 0.75% | 71 | -7.79% | 38 | 26.67% |
| Dec 31, 2024 | 126 | 0.80% | 48,891,669 | 0.99% | 104 | 0.95% | 71 | 4.41% | 31 | 3.33% |
| Sep 30, 2024 | 125 | 2.46% | 48,412,312 | 0.37% | 104 | 0.86% | 68 | 7.94% | 30 | -9.09% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| American Funds SMALLCAP World A | 3.18M | 6.36% | - |
| Vanguard Total Stock Mkt Idx Inv | 1.37M | 2.74% | -30.35K |
| Vanguard US Total Market Shares ETF | 1.20M | 2.41% | - |
| APO Medical Opportunities R | 1.17M | 2.31% | 866.80K |
| iShares Russell 2000 ETF | 919.58K | 1.82% | - |
| International Biotechnology Ord | 651.94K | 1.29% | 77.41K |
| SPDR® S&P Biotech ETF | 571.42K | 1.13% | 1.27K |
| MEDICAL BioHealth EUR Acc | 448.67K | 0.89% | 63.00K |
| Vanguard Institutional Extnd Mkt Idx Tr | 408.90K | 0.82% | -176.97K |
| Emerald Growth A | 405.00K | 0.80% | 47.67K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 08, 2025 | Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Sell | $120.42K |
| Nov 24, 2025 | Sweeny Nicole | Chief Commercial Officer | Sell | $51.29K |
| Nov 24, 2025 | Piekos Brian | Chief Financial Officer | Sell | $60.14K |
| Nov 24, 2025 | Yea Christopher | CHIEF DEVELOPMENT OFFICER | Sell | $58.26K |
| Nov 24, 2025 | Audhya Paul K. | CHIEF MEDICAL OFFICER | Sell | $71.24K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q4 | - | 10 |
| 2025 Q3 | - | 13 |
| 2025 Q2 | 1 | 9 |
| 2025 Q1 | 8 | 6 |
| 2024 Q4 | - | 6 |
KALV Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools